SANDY JEAN JELLEN
LA JOLLA, CA
Browse related groups: CA Pharmacosmos Therapeutics Inc. All categories
General Payments — all program years on this page
$1,540.40
- Category: General Payments
- Program years: PY2022–2023
- Record count: 9
- As of (CMS publication): 2026-01-23
Latest program year (PY2023): $1,420.63 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2023) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Honoraria | $700.00 | 1 |
| Food and Beverage | $621.63 | 6 |
| Education | $99.00 | 1 |
By paying entity
Latest program year (PY2023) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | $700.00 | 1 |
| GENZYME CORPORATION | $126.60 | 1 |
| Gilead Sciences, Inc. | $124.99 | 1 |
| Acerta Pharma LLC | $124.99 | 1 |
| E.R. Squibb & Sons, L.L.C. | $121.83 | 1 |
| Kite Pharma, Inc. | $102.47 | 1 |
| ABBVIE INC. | $99.00 | 1 |
| Pharmacyclics LLC, An AbbVie Company | $20.75 | 1 |
By program year
Records — PY2023 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1011940317 | AstraZeneca Pharmaceuticals LP | $124.99 | 05/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1013720009 | ABBVIE INC. | $99.00 | 10/06/2023 | Education | Undisputed | 01/23/2026 | View at CMS |
| 1015939407 | E.R. Squibb & Sons, L.L.C. | $121.83 | 05/18/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1046275813 | Pharmacosmos Therapeutics Inc. | $700.00 | 05/02/2023 | Honoraria | Undisputed | 01/23/2026 | View at CMS |
| 1050027665 | GENZYME CORPORATION | $126.60 | 10/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1112694243 | Kite Pharma, Inc. | $102.47 | 04/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1117482644 | Gilead Sciences, Inc. | $124.99 | 04/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 998304211 | Pharmacyclics LLC, An AbbVie Company | $20.75 | 08/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.